Change Language

Select Language

Press Release:

Global Hemophilia Market to Reach US$ 20.1 Billion by 2027, Impelled by Surging Number of Hemophilic Patients

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Hemophilia Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Market Overview:

The global hemophilia market reached a value of US$ 10.5 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 20.1 Billion by 2027, exhibiting a CAGR of 11.5% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor. 

Hemophilia is a rare disorder wherein the blood clotting process is slowed due to the lack of sufficient blood-clotting proteins. Patients with this condition experience prolonged bleeding or oozing after an injury, surgery, or a tooth is pulled. In severe cases, continuous bleeding may also occur after minor trauma or even in the absence of injury. On the other hand, its milder form does not involve spontaneous bleeding. As a result, the condition may not become apparent until abnormal bleeding occurs.

Hemophilia Market Trends:

The rising number of hemophilic patients around the world represents one of the key factors propelling the growth of the market. Additionally, the increasing diagnosis rate and the growing use of prophylactic treatment for hemophilia are offering lucrative growth opportunities to leading market players. Apart from this, due to the availability of limited treatment therapy, governing agencies of numerous countries are funding research and development (R&D) activities to identify therapeutic agents. They are also launching numerous campaigns to generate awareness about early diagnosis and undertaking initiatives to commence early screening of neonates. This is positively influencing the need for diagnostic tools of hemophilia worldwide. Besides this, the rising number of organizations like the World Federation of Hemophilia (WFH) and the National Hemophilia Foundation (NHF) is also impelling the market growth. These organizations help find treatments for inheritable bleeding disorders and prevent complications of these disorders through education, research, and advocacy. Furthermore, several companies are adopting strategies for increasing their sales and geographic expansion, especially in the Middle Eastern and West African countries. For instance, BioMarin Pharmaceutical Inc. is focusing on the development of Valoctocogene Roxaparvovec (BMN-270) for treating type A patients.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hemophilia market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, treatment and therapy.

Breakup by Type:

  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Others
     

Breakup by Treatment:

  • On-Demand
  • Prophylaxis
     

Breakup by Therapy:

  • Replacement Therapy
  • ITI Therapy
  • Gene Therapy
     

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Baxter International Inc., Bayer AG, BioMarin Pharmaceutical Inc., CSL Behring (CSL Limited), F. Hoffmann-La Roche AG, Grifols S.A., Kedrion S.p.A., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.

Report Coverage:

Report Features Details
Base Year of the Analysis 2021
Historical Period 2016-2021
Forecast Period 2022-2027
Units US$ Billion
Segment Coverage Type, Treatment, Therapy, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Baxter International Inc., Bayer AG, BioMarin Pharmaceutical Inc., CSL Behring (CSL Limited), F. Hoffmann-La Roche AG, Grifols S.A., Kedrion S.p.A., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Key Questions Answered in This Report:

  • How has the global hemophilia market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global hemophilia market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the treatment?
  • What is the breakup of the market based on the therapy?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global hemophilia market and who are the key players?
  • What is the degree of competition in the industry?

1   Preface
2   Scope and Methodology
    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3   Executive Summary
4   Introduction
    4.1    Overview
    4.2    Key Industry Trends
5   Global Hemophilia Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Forecast
6   Market Breakup by Type
    6.1    Hemophilia A
        6.1.1 Market Trends
        6.1.2 Market Forecast
    6.2    Hemophilia B
        6.2.1 Market Trends
        6.2.2 Market Forecast
    6.3    Hemophilia C
        6.3.1 Market Trends
        6.3.2 Market Forecast
    6.4    Others
        6.4.1 Market Trends
        6.4.2 Market Forecast
7   Market Breakup by Treatment
    7.1    On-Demand
        7.1.1 Market Trends
        7.1.2 Market Forecast
    7.2    Prophylaxis
        7.2.1 Market Trends
        7.2.2 Market Forecast
8   Market Breakup by Therapy
    8.1    Replacement Therapy
        8.1.1 Market Trends
        8.1.2 Market Forecast
    8.2    ITI Therapy
        8.2.1 Market Trends
        8.2.2 Market Forecast
    8.3    Gene Therapy
        8.3.1 Market Trends
        8.3.2 Market Forecast
9   Market Breakup by Region
    9.1    North America
        9.1.1 United States
           9.1.1.1 Market Trends
           9.1.1.2 Market Forecast
        9.1.2 Canada
           9.1.2.1 Market Trends
           9.1.2.2 Market Forecast
    9.2    Asia-Pacific
        9.2.1 China
           9.2.1.1 Market Trends
           9.2.1.2 Market Forecast
        9.2.2 Japan
           9.2.2.1 Market Trends
           9.2.2.2 Market Forecast
        9.2.3 India
           9.2.3.1 Market Trends
           9.2.3.2 Market Forecast
        9.2.4 South Korea
           9.2.4.1 Market Trends
           9.2.4.2 Market Forecast
        9.2.5 Australia
           9.2.5.1 Market Trends
           9.2.5.2 Market Forecast
        9.2.6 Indonesia
           9.2.6.1 Market Trends
           9.2.6.2 Market Forecast
        9.2.7 Others
           9.2.7.1 Market Trends
           9.2.7.2 Market Forecast
    9.3    Europe
        9.3.1 Germany
           9.3.1.1 Market Trends
           9.3.1.2 Market Forecast
        9.3.2 France
           9.3.2.1 Market Trends
           9.3.2.2 Market Forecast
        9.3.3 United Kingdom
           9.3.3.1 Market Trends
           9.3.3.2 Market Forecast
        9.3.4 Italy
           9.3.4.1 Market Trends
           9.3.4.2 Market Forecast
        9.3.5 Spain
           9.3.5.1 Market Trends
           9.3.5.2 Market Forecast
        9.3.6 Russia
           9.3.6.1 Market Trends
           9.3.6.2 Market Forecast
        9.3.7 Others
           9.3.7.1 Market Trends
           9.3.7.2 Market Forecast
    9.4    Latin America
        9.4.1 Brazil
           9.4.1.1 Market Trends
           9.4.1.2 Market Forecast
        9.4.2 Mexico
           9.4.2.1 Market Trends
           9.4.2.2 Market Forecast
        9.4.3 Others
           9.4.3.1 Market Trends
           9.4.3.2 Market Forecast
    9.5    Middle East and Africa
        9.5.1 Market Trends
        9.5.2 Market Breakup by Country
        9.5.3 Market Forecast
10  SWOT Analysis
    10.1    Overview
    10.2    Strengths
    10.3    Weaknesses
    10.4    Opportunities
    10.5    Threats
11  Value Chain Analysis
12  Porters Five Forces Analysis
    12.1    Overview
    12.2    Bargaining Power of Buyers
    12.3    Bargaining Power of Suppliers
    12.4    Degree of Competition
    12.5    Threat of New Entrants
    12.6    Threat of Substitutes
13  Price Analysis
14  Competitive Landscape
    14.1    Market Structure
    14.2    Key Players
    14.3    Profiles of Key Players
        14.3.1    Baxter International Inc.
           14.3.1.1 Company Overview
           14.3.1.2 Product Portfolio
           14.3.1.3 Financials
           14.3.1.4 SWOT Analysis
        14.3.2    Bayer AG
           14.3.2.1 Company Overview
           14.3.2.2 Product Portfolio
           14.3.2.3 Financials
           14.3.2.4 SWOT Analysis
        14.3.3    BioMarin Pharmaceutical Inc.
           14.3.3.1 Company Overview
           14.3.3.2 Product Portfolio
           14.3.3.3 Financials
           14.3.3.4 SWOT Analysis
        14.3.4    CSL Behring (CSL Limited)
           14.3.4.1 Company Overview
           14.3.4.2 Product Portfolio
        14.3.5    F. Hoffmann-La Roche AG
           14.3.5.1 Company Overview
           14.3.5.2 Product Portfolio
           14.3.5.3 Financials
        14.3.6    Grifols S.A.
           14.3.6.1 Company Overview
           14.3.6.2 Product Portfolio
           14.3.6.3 Financials
           14.3.6.4 SWOT Analysis
        14.3.7    Kedrion S.p.A.
           14.3.7.1 Company Overview
           14.3.7.2 Product Portfolio
        14.3.8    Novo Nordisk A/S
           14.3.8.1 Company Overview
           14.3.8.2 Product Portfolio
           14.3.8.3 Financials
           14.3.8.4 SWOT Analysis
        14.3.9    Octapharma AG
           14.3.9.1 Company Overview
           14.3.9.2 Product Portfolio
           14.3.9.3 SWOT Analysis
        14.3.10    Pfizer Inc.
           14.3.10.1 Company Overview
           14.3.10.2 Product Portfolio
           14.3.10.3 Financials
           14.3.10.4 SWOT Analysis
        14.3.11    Sanofi S.A.
           14.3.11.1 Company Overview
           14.3.11.2 Product Portfolio
           14.3.11.3 Financials
           14.3.11.4 SWOT Analysis
        14.3.12    Takeda Pharmaceutical Company Limited
           14.3.12.1 Company Overview
           14.3.12.2 Product Portfolio
           14.3.12.3 Financials
           14.3.12.4 SWOT Analysis

List of Figures

Figure 1: Global: Hemophilia Market: Major Drivers and Challenges
Figure 2: Global: Hemophilia Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Hemophilia Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 4: Global: Hemophilia Market: Breakup by Type (in %), 2021
Figure 5: Global: Hemophilia Market: Breakup by Treatment (in %), 2021
Figure 6: Global: Hemophilia Market: Breakup by Therapy (in %), 2021
Figure 7: Global: Hemophilia Market: Breakup by Region (in %), 2021
Figure 8: Global: Hemophilia (Hemophilia A) Market: Sales Value (in Million US$), 2016 & 2021
Figure 9: Global: Hemophilia (Hemophilia A) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 10: Global: Hemophilia (Hemophilia B) Market: Sales Value (in Million US$), 2016 & 2021
Figure 11: Global: Hemophilia (Hemophilia B) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 12: Global: Hemophilia (Hemophilia C) Market: Sales Value (in Million US$), 2016 & 2021
Figure 13: Global: Hemophilia (Hemophilia C) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 14: Global: Hemophilia (Other Types) Market: Sales Value (in Million US$), 2016 & 2021
Figure 15: Global: Hemophilia (Other Types) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 16: Global: Hemophilia (On-Demand) Market: Sales Value (in Million US$), 2016 & 2021
Figure 17: Global: Hemophilia (On-Demand) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 18: Global: Hemophilia (Prophylaxis) Market: Sales Value (in Million US$), 2016 & 2021
Figure 19: Global: Hemophilia (Prophylaxis) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 20: Global: Hemophilia (Replacement Therapy) Market: Sales Value (in Million US$), 2016 & 2021
Figure 21: Global: Hemophilia (Replacement Therapy) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 22: Global: Hemophilia (ITI Therapy) Market: Sales Value (in Million US$), 2016 & 2021
Figure 23: Global: Hemophilia (ITI Therapy) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 24: Global: Hemophilia (Gene Therapy) Market: Sales Value (in Million US$), 2016 & 2021
Figure 25: Global: Hemophilia (Gene Therapy) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 26: North America: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 27: North America: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 28: United States: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 29: United States: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 30: Canada: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 31: Canada: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 32: Asia-Pacific: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 33: Asia-Pacific: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 34: China: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 35: China: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 36: Japan: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 37: Japan: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 38: India: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 39: India: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 40: South Korea: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 41: South Korea: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 42: Australia: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 43: Australia: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 44: Indonesia: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 45: Indonesia: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 46: Others: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 47: Others: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 48: Europe: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 49: Europe: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 50: Germany: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 51: Germany: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 52: France: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 53: France: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 54: United Kingdom: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 55: United Kingdom: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 56: Italy: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 57: Italy: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 58: Spain: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 59: Spain: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 60: Russia: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 61: Russia: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 62: Others: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 63: Others: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 64: Latin America: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 65: Latin America: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 66: Brazil: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 67: Brazil: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 68: Mexico: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 69: Mexico: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 70: Others: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 71: Others: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 72: Middle East and Africa: Hemophilia Market: Sales Value (in Million US$), 2016 & 2021
Figure 73: Middle East and Africa: Hemophilia Market: Breakup by Country (in %), 2021
Figure 74: Middle East and Africa: Hemophilia Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 75: Global: Hemophilia Industry: SWOT Analysis
Figure 76: Global: Hemophilia Industry: Value Chain Analysis
Figure 77: Global: Hemophilia Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Hemophilia Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Hemophilia Market Forecast: Breakup by Type (in Million US$), 2022-2027
Table 3: Global: Hemophilia Market Forecast: Breakup by Treatment (in Million US$), 2022-2027
Table 4: Global: Hemophilia Market Forecast: Breakup by Therapy (in Million US$), 2022-2027
Table 5: Global: Hemophilia Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 6: Global: Hemophilia Market: Competitive Structure
Table 7: Global: Hemophilia Market: Key Players

Note: We value your privacy and will never rent or sell your email address. Privacy policy

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Related Report

Medical Specialty Bags Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Read More

Medical Spa Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Read More

Medical Foam Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Read More

Cord Blood Banking Services Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Read More

Separation Systems for Commercial Biotechnology Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Read More

Purchase Options




$ 2499

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )

Drop us an email at

sales@imarcgroup.com

Social Links